Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last?
- PMID: 33454881
- DOI: 10.1245/s10434-020-09400-x
Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last?
References
-
- Grossberg AJ, Chu LC, Deig CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70:375–403. - DOI
-
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. - DOI
-
- Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. - DOI
-
- Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85. - DOI
-
- Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. Jama. 2012;308(2):147–56. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
